{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:19:20Z","timestamp":1790036360676,"version":"4.0.1"},"reference-count":30,"publisher":"American Diabetes Association","issue":"4","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,4,1]]},"abstract":"<jats:p>Insulin pump therapy, also known as continuous subcutaneous insulin infusion (CSII), is an important and evolving form of insulin delivery, which is mainly used for people with type 1 diabetes. However, even with modern insulin pumps, errors of insulin infusion can occur due to pump failure, insulin infusion set (IIS) blockage, infusion site problems, insulin stability issues, user error, or a combination of these. Users are therefore exposed to significant and potentially fatal hazards: interruption of insulin infusion can result in hyperglycemia and ketoacidosis; conversely, delivery of excessive insulin can cause severe hypoglycemia. Nevertheless, the available evidence on the safety and efficacy of CSII remains limited. The European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) have therefore joined forces to review the systems in place for evaluating the safety of pumps from a clinical perspective. We found that useful information held by the manufacturing companies is not currently shared in a sufficiently transparent manner. Public availability of adverse event (AE) reports on the US Food and Drug Administration\u2019s Manufacturer and User Facility Device Experience (MAUDE) database is potentially a rich source of safety information but is insufficiently utilized due to the current configuration of the system; the comparable database in Europe (European Databank on Medical Devices [EUDAMED]) is not publicly accessible. Many AEs appear to be attributable to human factors and\/or user error, but the extent to which manufacturing companies are required by regulators to consider the interactions of users with the technical features of their products is limited. The clinical studies required by regulators prior to marketing are small and over-reliant on bench testing in relation to \u201cpredicate\u201d products. Once a pump is available on the market, insufficient data are made publicly available on its long-term use in a real-world setting; such data could provide vital information to help health care teams to educate and support users and thereby prevent AEs. As well as requiring more from the manufacturing companies, we call for public funding of more research addressing clinically important questions in relation to pump therapy: both observational studies and clinical trials. At present, there are significant differences in the regulatory systems between the US and European Union at both pre- and postmarketing stages; improvements in the European system are more urgently required. This statement concludes with a series of recommended specific actions for \u201cmeknovigilance\u201d (i.e., a standardized safety approach to technology) that could be implemented to address the shortcomings we highlight.<\/jats:p>","DOI":"10.2337\/dc15-0168","type":"journal-article","created":{"date-parts":[[2015,3,17]],"date-time":"2015-03-17T03:27:03Z","timestamp":1426562823000},"page":"716-722","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":116,"title":["Insulin Pump Risks and Benefits: A Clinical Appraisal of Pump Safety Standards, Adverse Event Reporting, and Research Needs"],"prefix":"10.2337","volume":"38","author":[{"given":"Lutz","family":"Heinemann","sequence":"first","affiliation":[{"name":"Science & Co, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Alexander","family":"Fleming","sequence":"additional","affiliation":[{"name":"Kinexum, Harpers Ferry, WV"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Petrie","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard W.","family":"Holl","sequence":"additional","affiliation":[{"name":"Institute of Epidemiology and Medical Biometry, ZIBMT, University of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Bergenstal","sequence":"additional","affiliation":[{"name":"International Diabetes Center at Park Nicollet, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne L.","family":"Peters","sequence":"additional","affiliation":[{"name":"Keck School of Medicine of the University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2015,3,16]]},"reference":[{"key":"2022031301332252900_B1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/bmj.1.6107.204","article-title":"Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia","volume":"1","author":"Pickup","year":"1978","journal-title":"BMJ"},{"key":"2022031301332252900_B2","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1089\/dia.2013.1503","article-title":"Insulin pumps","volume":"15","author":"Pickup","year":"2013","journal-title":"Diabetes Technol Ther"},{"key":"2022031301332252900_B3","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/jama.2013.277818","article-title":"Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial","volume":"310","author":"Ly","year":"2013","journal-title":"JAMA"},{"key":"2022031301332252900_B4","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1303576","article-title":"Threshold-based insulin-pump interruption for reduction of hypoglycemia","volume":"369","author":"Bergenstal","year":"2013","journal-title":"N Engl J Med"},{"key":"2022031301332252900_B5","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4158\/EP14145.PS","article-title":"Consensus statement by the American Association of Clinical Endocrinologists\/American College of Endocrinology Insulin Pump Management Task Force","volume":"20","author":"Grunberger","year":"2014","journal-title":"Endocr Pract"},{"key":"2022031301332252900_B6","unstructured":"Diabetes\u2008UK. Insulin pump therapy. Also known as continuous subcutaneous insulin infusion (CSII). Position statement (updated September 2011). Available from www.diabetes.org.uk\/Documents\/Position%20statements\/Position_Statment_Insulin_pump_therapy090911.pdf. Accessed 24 December 2014"},{"key":"2022031301332252900_B7","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1089\/dia.2009.0161","article-title":"The use of insulin pumps in youth with type 1 diabetes","volume":"12","author":"Maahs","year":"2010","journal-title":"Diabetes Technol Ther"},{"key":"2022031301332252900_B8","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1210\/jc.2012-1561","article-title":"The T1D Exchange clinic registry","volume":"97","author":"Beck","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031301332252900_B9","unstructured":"Close Concerns. Medtronic issues class II recall for MiniMed Paradigm and 530G systems [Internet], 2014. Available from www.closeconcerns.com\/knowledgebase\/r\/846b6e3d. Accessed 24 December 2014"},{"key":"2022031301332252900_B10","unstructured":"US Food and Drug Administration. Infusion pumps total product life cycle. Guidance for industry and FDA staff [Internet], 2014. Available from www.fda.gov\/downloads\/MedicalDevices\/DeviceRegulationandGuidance\/GuidanceDocuments\/UCM209337.pdf. Accessed 22 January 2015"},{"key":"2022031301332252900_B11","unstructured":"US Food and Drug Administration. Draft guidance for industry and Food and Drug Administration staff - medical device reporting for manufacturers [Internet], 2013. Available from www.fda.gov\/MedicalDevices\/DeviceRegulationandGuidance\/GuidanceDocuments\/ucm359130.htm. Accessed 25 October 2014"},{"key":"2022031301332252900_B12","unstructured":"US Food and Drug Administration. Deciding when to submit a 510(k) for a change to an existing device (K97-1) [Internet], 1997. Available from www.fda.gov\/MedicalDevices\/DeviceRegulationandGuidance\/GuidanceDocuments\/ucm080235.htm. Accessed 25 October 2014"},{"key":"2022031301332252900_B13","unstructured":"Council of the European Union. Council Directive 93\/42\/EEC of 14 June 1993 concerning medical devices [Internet], 1993. Available from http:\/\/eur-lex.europa.eu\/legal-content\/en\/ALL\/;ELX_SESSIONID=YJQGJLGd1JrpT98QbJKC8KMcchrTtQfzj1fjznyTjVv1p2vfp6bh!283099387?uri=CELEX:31993L0042. Accessed 25 October 2014"},{"key":"2022031301332252900_B14","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMhle1113918","article-title":"Regulation of medical devices in the United States and European Union","volume":"366","author":"Kramer","year":"2012","journal-title":"N Engl J Med"},{"key":"2022031301332252900_B15","unstructured":"European Commission DG Health and Consumers (SANCO). Guidelines on a Medical Devices Vigilance System [Internet], 2013. Available from http:\/\/ec.europa.eu\/health\/medical-devices\/files\/meddev\/2_12_1_ol_en.pdf. Accessed 11 November 2014"},{"key":"2022031301332252900_B16","doi-asserted-by":"crossref","first-page":"e1133","DOI":"10.1542\/peds.2007-1707","article-title":"Adolescent use of insulin and patient-controlled analgesia pump technology: a 10-year Food and Drug Administration retrospective study of adverse events","volume":"121","author":"Cope","year":"2008","journal-title":"Pediatrics"},{"key":"2022031301332252900_B17","first-page":"A247","article-title":"Absorption kinetics of insulin following subcutaneous bolus administration with different bolus durations","volume":"62","author":"Regittnig","year":"2013","journal-title":"Diabetes"},{"key":"2022031301332252900_B18","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1177\/193229680900300631","article-title":"Insulin pump therapy: what is the evidence for using different types of boluses for coverage of prandial insulin requirements?","volume":"3","author":"Heinemann","year":"2009","journal-title":"J Diabetes Sci Tech"},{"key":"2022031301332252900_B19","unstructured":"US Food and Drug Administration. Human factors and medical devices [Internet], 2014. Available from www.fda.gov\/MedicalDevices\/DeviceRegulationandGuidance\/HumanFactors\/. Accessed 25 October 2014"},{"key":"2022031301332252900_B20","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.diabet.2013.05.006","article-title":"Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes","volume":"39","author":"Blanco","year":"2013","journal-title":"Diabetes Metab"},{"key":"2022031301332252900_B21","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1177\/193229681200600429","article-title":"Insulin infusion set: the Achilles heel of continuous subcutaneous insulin infusion","volume":"6","author":"Heinemann","year":"2012","journal-title":"J Diabetes Sci Tech"},{"key":"2022031301332252900_B22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2337\/diacare.9.4.351","article-title":"Malfunction of continuous subcutaneous insulin infusion systems: a one-year prospective study of 127 patients","volume":"9","author":"Mecklenburg","year":"1986","journal-title":"Diabetes Care"},{"key":"2022031301332252900_B23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/pedi.12067","article-title":"A contrast between children and adolescents with excellent and poor control: the T1D Exchange clinic registry experience","volume":"15","author":"Campbell","year":"2014","journal-title":"Pediatr Diabetes"},{"key":"2022031301332252900_B24","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.2337\/dc12-2643","article-title":"Differences in the management of type 1 diabetes among adults under excellent control compared with those under poor control in the T1D Exchange Clinic Registry","volume":"36","author":"Simmons","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031301332252900_B25","unstructured":"Lee\u2008JM. Glu together as one: an innovative online social network for engaging patients with type 1 diabetes and their caregivers and advancing research to improve the lives of patients with type 1 diabetes [Internet], 2012. Available from http:\/\/medicinex.stanford.edu\/jlee-abstract\/. Accessed 25 October 2014"},{"key":"2022031301332252900_B26","first-page":"A196","article-title":"Insulin pumps (CSII) and cardiovascular diseases and mortality in the Swedish national diabetes register","volume":"57","author":"Gudbj\u00f6rnsdottir","year":"2014","journal-title":"Diabetologia"},{"key":"2022031301332252900_B27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1262-3636(07)70281-1","article-title":"Technical risks with subcutaneous insulin infusion","volume":"32","author":"Guilhem","year":"2006","journal-title":"Diabetes Metab"},{"key":"2022031301332252900_B28","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1007\/s00125-009-1549-7","article-title":"Insulin pump failures are still frequent: a prospective study over 6 years from 2001 to 2007","volume":"52","author":"Guilhem","year":"2009","journal-title":"Diabetologia"},{"key":"2022031301332252900_B29","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1399-5448.2010.00701.x","article-title":"Factors associated with increased risk of insulin pump discontinuation in pediatric patients with type 1 diabetes","volume":"12","author":"de Vries","year":"2011","journal-title":"Pediatr Diabetes"},{"key":"2022031301332252900_B30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1399-5448.2009.00546.x","article-title":"Discontinuation of insulin pump treatment in children, adolescents, and young adults. A multicenter analysis based on the DPV database in Germany and Austria","volume":"11","author":"Hofer","year":"2010","journal-title":"Pediatr Diabetes"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/38\/4\/716\/623472\/dc150168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/38\/4\/716\/623472\/dc150168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T05:26:33Z","timestamp":1647149193000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/38\/4\/716\/37581\/Insulin-Pump-Risks-and-Benefits-A-Clinical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,16]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,3,16]]},"published-print":{"date-parts":[[2015,4,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc15-0168","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,16]]}}}